Journal of Neuro-Oncology

, Volume 59, Issue 2, pp 157–163 | Cite as

Salvage Chemotherapy with CPT-11 for Recurrent Oligodendrogliomas

  • Marc C. Chamberlain


Objective: A prospective Phase I study designed to establish the maximum tolerated dose and secondarily evaluate response rate to CPT-11 in patients with recurrent oligodendrogliomas (oligos) on anticonvulsant drugs (AEDs).

Background: Oligos, which constitute 1–2% for all adult brain tumors, are commonly treated with procarbazine, CCNU and vincristine (PCV) chemotherapy. How to treat oligos that have failed PCV, surgery and radiotherapy is more problematic.

Design/Methods: Fifteen patients (age range 24–55 years; gender 10 males; 5 females) with recurrent oligos and on AEDs were treated prospectively with CPT-11. Four cohorts of patients defined by CPT-11 dose were treated. Three patients were treated with 400 mg/m2 every 3 weeks, 3 patients 500 mg/m2, 6 patients 600 mg/m2 and 3 patients 700 mg/m2. Neuroradiographic evaluation was performed after every other dose of CPT-11. In patients with stable or responding disease, two further doses of CPT-11 were administered. Alternative or supportive care was offered to patients with disease progression.

Results: Toxicity included neutropenia (3 patients; 1 each with Grade III and Grade IV toxicity); thrombocytopenia (2 patients; 1 with Grade IV toxicity); abdominal pain with or without diarrhea (5 patients; 1 with Grade III toxicity) nausea/vomiting (4 patients). No patient required hospitalization nor did a treatment-related death occur. One patient required a platelet transfusion. Toxicity was a function of CPT-11 dose and the maximum tolerated dose was 600 mg/m2. Cycles (2–12) of CPT-11 were administered (median 4). Response was as follows: partial response (2 patients); stable disease (5 patients); and progressive disease (8 patients). Duration of response ranged from 1.5 to 9 months with a median of 3. In patients with either stable disease or a partial response, response duration was 4.5–9 months (median 6 months). Progression-free survival at 6 months was 33% and 0% at 12 months. Overall survival following initiation of CPT-11 ranged from 2 to 12 months (median 3 months). In patients with either stable or responding disease, median survival was 7 months (range 6–12 months).

Conclusion: In this small cohort of patients with recurrent low-grade oligos having been treated previously with PCV and on cytochrome P450 enzyme inducing AEDs, CPT-11 has modest palliative efficacy and acceptable toxicity. A dose of 600 mg/m2 every 3 weeks of CPT-11 in patients on AEDs is suggested based on toxicity analysis.

chemotherapy CPT-II oligodendrogliomas phase I 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Calli P, Nofrone I, Palma L Cantore G, Fortuna A: Cerebral oligodendrogliomas: prognostic factors and life history. Neurosurgery 35: 1018–1035, 1994Google Scholar
  2. 2.
    Daumas-Duport C, Varlet P, Tucker ML, Beuvon F, Cervera P, Chodkiewicz JP: Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: A study of 153 cases. J Neuro-Oncol 34: 37–59, 1997Google Scholar
  3. 3.
    DeAngelis LM: Brain tumors. NEJM 344(2): 114–123, 2001Google Scholar
  4. 4.
    Lindegaard KF, Mork SJ, Eide GE, Halvorsen TB, Hatlevoll R, Solgaard T, Dahl O, Ganz J: Statistical analysis of clinicopathological features, radiotherapy, and survival in 170 cases of oligodendroglioma. J Neurosurg 67: 224–230, 1987Google Scholar
  5. 5.
    Ludwig CL, Smith MT, Godfrey AD, Armbrustmacher VW: A clinicopathological study of 323 patients with oligodendrogliomas. Ann Neurol 19: 15–21, 1986Google Scholar
  6. 6.
    Paleologos NA: Oligodendroglioma. J Neurol 3: 59–66, 2001Google Scholar
  7. 7.
    Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis DH: Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 76: 428–434, 1992Google Scholar
  8. 8.
    Wallner KE, Gonzales M, Sheline GE: Treatment of oligodendrogliomas with or without postoperative irradiation. J Neurosurg 68: 684–688, 1988Google Scholar
  9. 9.
    Leighton G, Fisher B, Bauman G, Depiero S, Stitt L, Macdonald D, Cairncross G: Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 15: 1294–1301, 1997Google Scholar
  10. 10.
    Brown M, Durham NC, Cairncross JG et al.: Differential response of recurrent oligodendrogliomas vs. astrocytomas to intravenous (IV) melphalan. Neurology 40(Suppl 1): 397, 1990 (Abstract)Google Scholar
  11. 11.
    Cairncross JG, Macdonald DR: Chemotherapy for oligodendroglioma. Arch Neurol 78: 225–227, 1991Google Scholar
  12. 12.
    Chamberlain MC, Kormanik PA: Salvage chemotherapy with Paclitaxel for recurrent oligodendrogliomas. J Clin Oncol 15: 3427–3432, 1997Google Scholar
  13. 13.
    Chinot O, Honore S, Barrie M, Dufour H, Brauger D, Grisoli F: Temodal (Temozolomide, TMZ) as secondline treatment following PCV in oligodendroglial tumors. Neuro-Oncol 2: 256, 2000 (Abstract)Google Scholar
  14. 14.
    Glass J, Hochberg FH, Gruber ML, Louis DN, Smith D, Rattner B: The treatment of oligodendrogliomas and mixed oligodendrogliomas astrocytomas with PCV chemotherapy. J Neurosurg 76: 741–745, 1992Google Scholar
  15. 15.
    Levin VA: Controversies in the treatment of low-grade astrocytomas and oligodendrogliomas. Curr Opin Oncol 8: 176–177, 1996Google Scholar
  16. 16.
    Mason WP, Krol GS, DeAngelis LM: Low-grade oligodendroglioma responds to chemotherapy. Neurology 46: 203–207, 1996Google Scholar
  17. 17.
    Olson JD, Riedel E, DeAngelis LM: Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54: 1442–1448, 2000Google Scholar
  18. 18.
    Paleologos NA, Cairncross JG: Treatment of oligodendroglioma: an update. Neuro-Oncol 1: 61–68, 1999Google Scholar
  19. 19.
    Paleologos NA, Vick NA, Kachoris JP: Chemotherapy for low-grade oligodendrogliomas? Ann Neurol 36: 294–295, 1994Google Scholar
  20. 20.
    Perry JR, Louis DN, Cairncross JG: Current treatment of oligodendrogliomas. Arch Neurol 56: 434–437, 1999Google Scholar
  21. 21.
    Peterson K, Paleologos N, Forsyth P, Macdonald DR, Cairncross JG: Salvage chemotherapy for oligodendroglioma. J Neurosurg 85: 597–601, 1996Google Scholar
  22. 22.
    van den Bent MJ, Eskes FALM, Keime-Guibert F, van den Bent MJ, Boogerd W, Bravo-Marques J, Taphoorn MJB, Kros JM, van de Rijt CDD, de Beule N, Baron B: Temozolomide chemotherapy in recurrent oligodendroglioma. Neuro-Oncol 2: 298, 2000 (Abstract)Google Scholar
  23. 23.
    van den Bent MJ, Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HGJ, Taphoorn MJB, Zonnenberg BA, Tijssen CC, Twijnstra A, Punt CJA, Boogerd W: Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Neurology 51: 1140–1145, 1998Google Scholar
  24. 24.
    Rostomily RC, Spence AM, Duong D: Multi-modality management of recurrent adult malignant gliomas: results of a phase 2 multi-agent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery 35: 378–388, 1994Google Scholar
  25. 25.
    Salcman M: Resection and re-operation in neuro-oncology: rationale and approach. Neurol Clin 3: 831–842, 1985Google Scholar
  26. 26.
    Hall WA, Djalilian HR, Sperduto PW, Cho KH, Gerbi BJ, Gibbons JP, Rohr M, Clark HB: Stereotactic radiosurgery for recurrent malignant gliomas. J Clin Oncol 13: 1642–1648, 1995Google Scholar
  27. 27.
    Cairncross JG, Ueki K, Zlatesou MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90: 1473–1479, 1998Google Scholar
  28. 28.
    Bauman GS, Ino Y, Ueki M, Zlatescu MC, Fisher BJ, Macdonald DR, Stitt L, Louis DN, Cairncross JG: Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendroglioma. J Radiation Oncol 48(Suppl 1): 2000 (Abstract)Google Scholar
  29. 29.
    Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, Wilson CB: Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18(2): 321–324, 1990Google Scholar
  30. 30.
    Friedman HS, Kerby T, Calvert H: Temozolomide and treatment of malignant glioma. Clin Cancer Res 6: 2585–2597, 2000Google Scholar
  31. 31.
    Macdonald DR, Cascino TL, Schold Jr SC, Cairncross JG: Response criteria for Phase II studies supratentorial malignant glioma. J Clin Oncol 8(7): 1277–1280, 1990Google Scholar
  32. 32.
    Gehan EA: The determination of the number of newpatients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13: 346–353, 1961Google Scholar
  33. 33.
    Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM: Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 19: 1501–1518, 2001Google Scholar
  34. 34.
    Saltz LB, Coz JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus Fluorouracil and Leucovorin for metastatic colorectal cancer. NEJM 343: 905–914, 2000Google Scholar
  35. 35.
    Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Calvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL: Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 14: 1516–1525, 1999Google Scholar
  36. 36.
    Fetell MR, Grossman SA, Balmaceda C: Clinical and pharmacologic study of preirradiation Taxol administrated as a 96-hour infusion in adults with newly diagnosed glioblastoma multiforme. Proc ASCO 13: 179, 1994 (Abstract)Google Scholar
  37. 37.
    Prados M, Kuhn J, Yung WKA, Robbins HI, Fink K, Greenberg H, Junck L, Cloughesy T, Chang S, Fine H, Schiff D, Nicholas MK, Jaeckle KA, Hess K, Wen P: Phase 1–2. Study of CPT-11 given every 3 weeks in patients with recurrent brain tumors, a North American Tumor Consortium Study. Neuro-Oncol 4(2): 287–288, 2000 (Abstract)Google Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Marc C. Chamberlain
    • 1
  1. 1.Department of NeurologyUSC/Norris Cancer CenterLos AngelesUSA

Personalised recommendations